Center for Proteomics, State Key Laboratory of Bio-Control, School of Life Sciences, Sun Yat-sen University, University City, Guangzhou 510006, People's Republic of China.
J Proteome Res. 2010 May 7;9(5):2573-83. doi: 10.1021/pr1000219.
Bacterium is still a major cause of many infectious diseases and a global threat to human health, aquaculture, and animal feeding. Prevention by vaccination is the most efficient and economical way of fighting bacterial diseases, but one of the persistent challenges to prevent bacterial infections and disease transmissions is the existence of multiple bacterial species, families, and genera and the lack of efficient polyvalent vaccines against them. The information on candidate immunogens for polyvalent vaccine development is elusive, as well. For the development of broad cross-protective vaccines, we have employed heterogeneous antiserum-based immunoproteomics approaches to identify antigenically similar outer membrane (OM) proteins that could be used as potential polyvalent vaccine candidates against Vibrio parahaemolyticus , V. alginolyticus , V. fluvialis , Aeromonas hydrophila , and A. sobria infections. VPA1435, VP0764, VPA1186, VP1061, and VP2850 could be recognized by at least three antisera and demonstrated significantly passive and active immune protection against V. parahaemolyticus infection in a crucian carp model. VP1061 and VP2850 induced higher immune and protective abilities than the other three OM proteins. Furthermore, the abilities of VP1061 and VP2850 in the generation of broad cross-protective immune reaction against the infections of V. alginolyticus , A. hydrophila , and Pseudomonas fluorescens were also investigated in fish and mouse models. Our results suggested that VP1061 and VP2850 could potentially be used as polyvalent vaccine candidates for the development of novel polyvalent vaccines against V. parahaemolyticus and other Gram-negative pathogens. On the basis of these results, characteristics of OM proteins as polyvalent vaccine candidates have been addressed.
细菌仍然是许多传染病的主要原因，也是全球人类健康、水产养殖和动物饲养的威胁。疫苗预防是对抗细菌性疾病最有效和最经济的方法，但预防细菌感染和疾病传播的持续挑战之一是存在多种细菌物种、科和属，以及缺乏针对它们的有效多价疫苗。候选免疫原用于多价疫苗开发的信息也难以捉摸。为了开发广泛的交叉保护疫苗，我们采用了基于异源抗血清的免疫蛋白质组学方法来鉴定抗原相似的外膜（OM）蛋白，这些蛋白可以作为针对副溶血弧菌、溶藻弧菌、弗氏弧菌、杀鲑气单胞菌和温和气单胞菌感染的潜在多价疫苗候选物。VPA1435、VP0764、VPA1186、VP1061 和 VP2850 至少可以被三种抗血清识别，并在鲫鱼模型中对副溶血弧菌感染表现出显著的被动和主动免疫保护。VP1061 和 VP2850 诱导的免疫和保护能力高于其他三种 OM 蛋白。此外，还在鱼类和小鼠模型中研究了 VP1061 和 VP2850 在产生针对溶藻弧菌、杀鲑气单胞菌和荧光假单胞菌感染的广泛交叉保护免疫反应的能力。我们的研究结果表明，VP1061 和 VP2850 可能被用作多价疫苗候选物，用于开发针对副溶血弧菌和其他革兰氏阴性病原体的新型多价疫苗。基于这些结果，探讨了 OM 蛋白作为多价疫苗候选物的特性。
